阿奇霉素成人药动学数据外推至儿科人群中的PBPK模型与异速生长模型的比较研究

梁露花, 秦凌峰, 詹地富, 魏一鸿, 姜希伟, 肖珅, 翟菲

中国药学杂志 ›› 2020, Vol. 55 ›› Issue (17) : 1470-1475.

PDF(1151 KB)
中国药学杂志
PDF(1151 KB)
中国药学杂志 ›› 2020, Vol. 55 ›› Issue (17) : 1470-1475. DOI: 10.11669/cpj.2020.17.012
论著

阿奇霉素成人药动学数据外推至儿科人群中的PBPK模型与异速生长模型的比较研究

  • 梁露花1,2, 秦凌峰1, 詹地富1, 魏一鸿1, 姜希伟1,2, 肖珅1,2, 翟菲1,2*
作者信息 +

A Comparative Study of PBPK Model and Allometric Growth Model of Azithromycin in Extrapolation of Adult Pharmacokinetic Data to Pediatric Population

  • LIANG Lu-hua1,2, QIN Ling-feng1, ZHAN Di-fu1, WEI Yi-hong1, JIANG Xi-wei1,2, XIAO Shen1,2, ZHAI Fei1,2*
Author information +
文章历史 +

摘要

目的 通过建立阿奇霉素的成人-儿童转化模型,为儿科临床用药提供指导性的建议,降低儿童用药风险,实现儿童临床个性化用药。方法 查阅相关文献,利用成人的临床阿奇霉素口服给药试验的受试者生理参数结合阿奇霉素的药物特异参数,通过建立异速生长模型,生理药动学(physiologically based pharmacokinetic,PBPK)模型,根据文献提取的儿童个体口服阿奇霉素临床数据验证这2个模型的参数缩放公式的正确性。进一步利用这2种模型模拟出儿童相关药动学参数并计算出这些参数的相对偏差和相对标准误差。结果 通过模拟发现2个模型得到的药动学参数cmax、tmax、AUC0-∞实测值接近,都在文献范围内,可认为2模型的参数转化公式正确。进一步计算参数的相对偏差和相对标准误差,成人-儿童PBPK预测模型的cmax、tmax、AUC0-∞的相对偏差和相对标准误差都比异速生长模型的小。结论 阿奇霉素PBPK模型预测儿童药动学参数较异速生长模型要好。本研究所应用的口服用药成人-儿童模型特异性参数的缩放公式,经阿奇霉素验证成功,可以外推至其他药物,为其他口服给药的成人-儿童模型转化提供便利。

Abstract

OBJECTIVE To establish an adult-pediatric transformation model of azithromycin to provide guiding recommendations for clinical using of pediatrics, reduce the risk of medicationfor children, and achieve clinical personalized medication for children. METHODS The relevant literature was reviewed. The physiological parameters of the azithromycin oral administration test in adults combined with the drug-specific parameters of azithromycin were used to establish an allometric growth model, PBPK model. According to the clinical data of oral azithromycin extracted from individual children, the correctness of the parameter scaling formulas of these two models was verified. These two models were further used to simulate the pharmacokinetic parameters of children and calculate the relative deviation and relative standard error of these parameters. RESULTS Through simulation, it is found that the pharmacokinetic parameters cmax、 tmax、 AUC0-∞ obtained by the two models are close to the measured values, which are all within the scope of the literature. It can be considered that the parameter conversion formulas of the two models are correct. Further, the relative deviation and relative standard error of the parameters are calculated, and the relative deviation and relative standard error of the adult-pediatric PBPK prediction model are smaller than those of the allometric growth model. CONCLUSION The azithromycin PBPK model predicts that children′s pharmacokinetic parameters are better than the allometric growth model. The scaling formula for the specific parameters of the oral-dose adult-child model used in this article, which was successfully verified by azithromycin, can be extrapolated to other drugs to facilitate the conversion of other oral-adulterated adult-pediatric models.

关键词

阿奇霉素 / PK-SIM软件 / PBPK模型 / 异速生长

Key words

azithromycin / PK-SIM software / PBPK model / allometric growth model

引用本文

EndNote

Ris (Procite)

Bibtex

导出引用
梁露花, 秦凌峰, 詹地富, 魏一鸿, 姜希伟, 肖珅, 翟菲. 阿奇霉素成人药动学数据外推至儿科人群中的PBPK模型与异速生长模型的比较研究[J]. 中国药学杂志, 2020, 55(17): 1470-1475 https://doi.org/10.11669/cpj.2020.17.012
LIANG Lu-hua, QIN Ling-feng, ZHAN Di-fu, WEI Yi-hong, JIANG Xi-wei, XIAO Shen, ZHAI Fei. A Comparative Study of PBPK Model and Allometric Growth Model of Azithromycin in Extrapolation of Adult Pharmacokinetic Data to Pediatric Population[J]. Chinese Pharmaceutical Journal, 2020, 55(17): 1470-1475 https://doi.org/10.11669/cpj.2020.17.012
中图分类号： R969.3   

参考文献

[1] CHI L Q, YU J X. Development of physiologically based pharmacokinetic modeling of vancomycin in healthy populations and tissue distribution prediction[J].Chin J Clin Pharm(中国临床药学杂志), 2019, 28(2):138-140.
[2] SHI J, JEFFREYS.B. Pharmacometrics in pediatric drug development and rational dosage[J]. Chin J Clin Pharmacol Ther(中国临床药理学与治疗学), 2010, 15(1): 1-10.
[3] SUNZ Y, JIAL R, LI D L, et al. The research progress and application of pharmacometrics[J]. J Shenyang Pharm Univ(沈阳药科大学学报),2018, 35(5):431-436.
[4] SHANGD W, WANGX P, DENGC H, et al. Application of pharmacometrics in drug developmen tandtherapeutic drug monitoring[J].J China Pharm Univ(中国药科大学学报), 2010, 41(1):91-96.
[5] WANG T, HEX N, ZHANG Z H, et al. Spectroscopic study on the interaction of azithromycin human serum albumin[J]. J Beijing Instit Petrochem Technol(北京石油化工学院学报),2011, 19(3):54-59.
[6] ZHANG X Y. Population pharmacokinetics study of azithromycin oral formulations using NONMEM[D]. Shenyang: Shenyang Pharmaceutical University, 2010.
[7] DrugBank. Drug and drug target database [DB/OL]. .http://www.drugbank.ca.
[8] FOULDSG, SHEPARDR M, JOHNSON R B .The pharmacokinetics of azithromycin in human serum and tissues[J]. J Antimicrob Chemother, 1990, 25(suppl A):73-82.
[9] NASIRI, TAWFIQA, HAZIMH, et al. Saliva versus plasma bioequivalence of azithromycin in humans: validation of class Ⅰ drugs of the salivary excretion classification system[J]. Drugs R D, 2017. DOI:10. 1007/s40268-016-0170-8.
[10] SCHILLERC, FROHLICHC P, GIESSMANNT, et al. Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging[J]. Aliment Pharmacol Ther, 2005, 22(12): 971-979.
[11] JOHNSON T N, JAMEI M, ROWLAND-YEO K. How does in vivo biliary elimination of drugs change with age? evidence from in vitro and clinical data using a systems pharmacology approach[J]. Drug Metab Dispos, 2016, 44(7):1090-1098.
[12] LALAKN J, MORRISD L. Azithromycin clinical pharmacokinetics[J]. Clin Pharmacokinet, 1993, 25(5):370-374.
[13] MILAPC N, KATALINI,DAVID R,et al. Pharmacokinetics of azithromycin in pediatric patients with acute otitis media[J]. Antimicro Agents Chemother, 1995, 39(8):1875-1877.
[14] MILAPC N, KATALINI K, SHRIKAND G, et al. Pharmacokinetics of azithromycin in pediatric patients after oral administration of multiple doses of suspension [J]. Antimicro Agents Chemother, 1993, 37(2):314-316.
[15] PAUL B, KITTY M T H, JANE K, et al. Absolute bioavailability and intracellular pharmacokinetics of azithromycin in patients with cystic fibrosis[J]. Antimicro Agents Chenotherapy, 2005, 49(12):5013-5017.
[16] ALFREDOP L, EVERARDOP G,OSCAR T A, et al. Bioavailability of two oral formulations of azithromycin 500 mg: a randomized, open-label, two-period crossover comparison in healthy mexican adult subjects[J]. Clin Ther, 2005, 10(27):1231-1239.
[17] MAIZBHAU A, MOHAMMADS I, HASANUZZAMANS, et al. Comparative pharmacokinetic and bioeqivalence study of azithromycin 500 mg tablet in healthy Bangladeshi volunteers[J]. Int J Clin Pharm Ther, 2012,6(50):452-458.
[18] CAROLINEP, ADELINES, SATOSHIM, et al. Unified approach for extrapolation and bridging of adult information in early-phase dose-finding paediatric studies[J]. Stat Methods Med Res, 2016, 27(6):1-18.
[19] MICHAEL J P, VESNA E H, EVANGELOS J, et al. Azithromycin: mechanisms of action and their relevance for clinical applications[J]. Pharm Ther, 2014, 143(2):225-245.
[20] NAHATAM C, KORANYIK I, LUKE D R, et al. Pharmacokinetics of azithromycin in pediatric patients with acute otitis media[J]. Antimicrob Agents Chemother, 1995, 39(8):1875-1877.
[21] ZHOU Y, HU B, WANG H Y, et al. Physiological pharmacokinetic model and its application in drug interaction research[J]. Chin J Clin Pharm (中国临床药理学杂志), 2013, 29(9):706-709.
[22] ZHANG L. Talking about the pharmacological action and clinical application value of azithromycin[J]. Seek Med Adv(求医问药), 2012, 10(6):200.
[23] KENDRICKJ G, CARRR R, ENSOMM H. Pediatric obesity: pharmacokinetics and implications for drug dosing[J]. Clin Ther, 2015, 37(9):1897-1923.
[24] EDITONA N, SCHMITTW, VOITHB, et al. A mechanistic approach for the scaling of clearance in children[J]. Clin Pharmacokinet, 2006, 45(7):683-704.
[25] PETITC, JULLIEN V, SAMSONA, et al. Designing a pediatric study for an antimalarial drug by using information from adults[J]. Antimicro Agents Chemother, 2016, 60(3):1481-1491.
[26] ANDREA N. E, WALTER S, STEFAN W. Development and evaluation of a generic physiologically based pharmacokinetic model for children[J]. Clin Pharmacokinet, 2006, 45 (10):1013-1034.

基金

辽宁省自然科学基金项目资助(20180550345,20180550823)

PDF(1151 KB)

333

Accesses

0

Citation

Detail
段落导航
相关文章

/

〈 〉